Literature DB >> 6780232

Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin.

W D Bussmann, D Passek, W Seidel, M Kaltenbach.   

Abstract

The effect of i.v. nitroglycerin administration on indexes of infarct size was examined in 31 patients with acute myocardial infarction. Serial creatine kinase (CK) and CK-MB isoenzyme determinations were used to calculate infarct size. Twenty-nine patients served as controls. Two subgroups of the study group were formed to evaluate differences between early and late intervention. In the first group (n = 22), continuous infusion of nitroglycerin over 48 hours was initiated within 8 hours (mean 4.5 hours) after the onset of symptoms. Peak CK activity for the nitroglycerin-treated patients (n = 9) in this subgroup was 544 U/1 vs 871 U/1 for the controls (n = 13) (p less than 0.05). The rate of CK release was reduced from 79 to 33 U/1.hr (58%), as was total CK and CK-MB release (p less than 0.02). Calculated infarct size was 69 gEq in the controls and 48 gEq in patients receiving nitroglycerin (CK-MB: 69 vs 43 gEq, p less than 0.05). In the late intervention subgroup, nitroglycerin therapy was begun more than 8 hours (mean 12.8 hours) after the onset of symptoms. Here, too, use of the agent was associated with lower peak CK and CK-MB levels as well as a reduction in calculated infarct size (p less than 0.05). Hemodynamic measurements, recorded every 4 hours, showed that nitroglycerin also reduced left ventricular filling pressure significantly and cardiac output increased. Blood pressure fell slightly, and systemic vascular resistance declined. The results indicate that i.v. nitroglycerin reduces CK and CK-MB release and thus calculated infarct size in both early and late intervention.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6780232     DOI: 10.1161/01.cir.63.3.615

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Reperfusion Injury: Basic Concepts and Protection Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

2.  Left ventricular apical aneurysm following primary percutaneous coronary intervention.

Authors:  Masayuki Mori; Kenichi Sakakura; Hiroshi Wada; Nahoko Ikeda; Hiroyuki Jinnouchi; Yoshitaka Sugawara; Norifumi Kubo; Shin-ichi Momomura; Junya Ako
Journal:  Heart Vessels       Date:  2012-10-23       Impact factor: 2.037

Review 3.  Cardiogenic shock.

Authors:  C E Handler
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

Review 4.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

5.  Monophosphoryl lipid A induces pharmacologic 'preconditioning' in rabbit hearts without concomitant expression of 70-kDa heat shock protein.

Authors:  K Yoshida; M M Maaieh; J B Shipley; M Doloresco; N L Bernardo; Y Z Qian; G T Elliott; R C Kukreja
Journal:  Mol Cell Biochem       Date:  1996-06-07       Impact factor: 3.396

6.  Nitrates in myocardial infarction: influence on infarct size, reperfusion, and ventricular remodelling.

Authors:  J L Morris; A G Zaman; J H Smyllie; J C Cowan
Journal:  Br Heart J       Date:  1995-04

Review 7.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

8.  A preliminary double-blind study of intravenous nitroglycerin in acute myocardial infarction.

Authors:  Y Lis; D Bennett; G Lambert; D Robson
Journal:  Intensive Care Med       Date:  1984       Impact factor: 17.440

Review 9.  Nitrates in acute myocardial infarction.

Authors:  J Kjekshus
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 10.  Pharmacology of endothelium-derived nitric oxide and nitrovasodilators.

Authors:  L J Ignarro; G Ross; J Tillisch
Journal:  West J Med       Date:  1991-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.